MannKind to Host Institutional Investor and Analyst Meeting
June 20 2018 - 4:01PM
Renowned Endocrinology Expert Presenting
Current Trends in Treatment and Management of Diabetes
MannKind Corporation (Nasdaq:MNKD) today announced that it will
host an invitation-only luncheon at Lotte New York Palace on
Wednesday, June 27, 2018 for institutional investors and analysts,
also accessible by live webcast (details below). This event
will feature leading endocrinologist, Steven V. Edelman, MD,
University of California - San Diego, who will discuss the current
and novel approaches to treatment and management of diabetes in
Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of
MannKind Corporation, will provide a corporate overview followed by
MannKind’s Chief Medical Officer, David Kendall, presenting the
latest Afrezza data released at the American Diabetes Association’s
78th Scientific Sessions held June 22-26, 2018. Dr. Edelman
and MannKind’s management team will be available to answer
questions at the conclusion of the event.
Dr. Edelman is a Professor of Medicine in the
Division of Endocrinology, Diabetes & Metabolism at the
University of California at San Diego (UCSD) and the Veterans
Affairs (VA) Healthcare System of San Diego and the Director of the
Diabetes Care Clinic, VA Medical Center. Dr. Edelman has strong
interests in education and patient advocacy. He is the founder and
director of Taking Control of Your Diabetes (TCOYD), a
not-for-profit organization with the goal of teaching and
motivating patients in diabetes self-care. Dr. Edelman was recently
named in US News and World Report amongst the top 1% of
endocrinologists in the United States.
This event is intended for institutional
investors, sell-side analysts, investment bankers, and business
development professionals only. Please RSVP in advance if you plan
to attend, as space is limited. For those who are unable to
attend in person, a live webcast and replay will be accessible via
the link here. If you would like to ask a question during the
live Q&A, please submit your request via email.
About Afrezza®
Available by prescription, Afrezza® (insulin
human) Inhalation Powder is a rapid-acting inhaled insulin
indicated to improve glycemic control in adult patients with
diabetes mellitus. Afrezza consists of a dry powder
formulation of human insulin delivered from a small and portable
inhaler. Administered at the beginning of a meal, Afrezza dissolves
rapidly upon inhalation to the lung and passes quickly into the
bloodstream (in less than one minute). This rapid absorption allows
Afrezza to begin reducing blood sugar levels within about 12
minutes of administration. Afrezza is available in 4-unit,
8-unit and 12-unit single-dose cartridges of insulin powder that
can be used, as prescribed by a health care professional, in
combination with other diabetes medications to achieve target blood
sugar levels. For Afrezza doses exceeding 12 units, patients
may use a combination of existing cartridge strengths. For more
information on Afrezza, please visit www.afrezza.com.
About MannKind
MannKind Corporation (Nasdaq:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
MannKind Contact:Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024